Data Sheet 1_Reversal of left ventricular hypertrophy with sacubitril/valsartan vs. standa

Eleven randomized controlled trials involving 851 patients with hypertension and cardiovascular remodeling were analyzed. This document presents a network meta-analysis comparing the efficacy of sacubitril/valsartan against standard antihypertensive agents for reversing left ventricular hypertrophy. The analysis was conducted by Weizhi Tang and uploaded to figshare in April 2026.

Use Cases

• Compare treatment effect sizes for left ventricular mass index regression based on the reported weighted mean differences.
• Assess the ranking of antihypertensive therapies based on the surface under the cumulative ranking curve (SUCRA) values.
• Evaluate secondary outcomes like blood pressure reduction and left ventricular ejection fraction impact mentioned in the results.
• Study the methodology for network meta-analysis of randomized controlled trials in a clinical context.

Strengths

• Analysis includes 11 randomized controlled trials.
• Results are based on data from 851 patients.
• Includes specific effect estimates with confidence intervals for primary comparisons.
• Document is licensed under CC-BY-4.0 for open reuse.

Limitations

• The underlying patient-level data is not provided; only the analysis document is available.
• Column-level documentation for any raw data is absent.
• The authors note substantial heterogeneity and low-to-very-low certainty of evidence for the main comparisons.

Provenance

Source

figshare, author Weizhi Tang.

Collection Method

Systematic review and network meta-analysis of trials from PubMed, Embase, Cochrane Library, CNKI, Wanfang Data, and SinoMed.

Time Range

Trials from database inception to December 2025.

Freshness

Last updated 2026-04-14 05:38:28.

Geography

null